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OBJECTIVES The aim of this study was to clarify the clinical relevance of ventricular tachyarrhythmias
assessed by 24-h ambulatory electrocardiograms (ECG) in a large, unique, and prospectively
evaluated athletic population.
BACKGROUND For athletes with ventricular tachyarrhythmias, the risk of sudden cardiac death associated
with participation in competitive sports is unresolved.
METHODS We assessed 355 competitive athletes with ventricular arrhythmias (VAs) on a 24-h
ambulatory (Holter) ECG that was obtained because of either palpitations, the presence of
3 premature ventricular depolarizations (PVDs) on resting 12-lead ECG, or both.
RESULTS Athletes were segregated into three groups: Group A with 2,000 PVDs/24 h (n  71);
Group B with 100 2,000 PVDs/24 h (n  153); and Group C with only 100 PVDs/24
h (n  131). Cardiac abnormalities were detected in 26 of the 355 study subjects (7%) and
were significantly more common in Group A (21/71, 30%) than in Group B (5/153, 3%) or
Group C athletes (0/131, 0% p  0.001). Only the 71 athletes in Group A were excluded
from competition. During follow-up (mean, 8 years), 70 of 71 athletes in Group A and each
of the 284 athletes in Groups B and C have survived without cardiovascular events. The
remaining Group A athlete died suddenly of arrhythmogenic right ventricular cardiomyop-
athy while participating in a field hockey game against medical advice.
CONCLUSIONS Frequent and complex ventricular tachyarrhythmias are common in trained athletes and are
usually unassociated with underlying cardiovascular abnormalities. Such VAs (when unasso-
ciated with cardiovascular abnormalities) do not convey adverse clinical significance, appear to
be an expression of “athlete’s heart syndrome,” and probably do not per se justify a
disqualification from competitive sports. (J Am Coll Cardiol 2002;40:446–52) © 2002 by
the American College of Cardiology Foundation
Sudden cardiac deaths occurring on the athletic field in
young and healthy-appearing sports participants, presum-
ably largely related to ventricular tachyarrhythmias, are
highly visible events that continue to generate great concern
within the lay and medical communities (1–5). However,
the risk associated with competitive sports in athletes with
ventricular tachyarrhythmias identifiable by Holter record-
ing is presently unresolved. Furthermore, although there are
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little data available regarding the long-term clinical signif-
icance of ventricular arrhythmias (VAs) in healthy-
appearing athletes (6), premature ventricular depolarizations
(PVDs) are a frequent finding in such individuals (7–9).
At present, it is unresolved whether such ventricular
tachyarrhythmias should be regarded as benign or poten-
tially life-threatening electrical disorders during intense
physical activity, in the presence or absence of structural
heart disease. Therefore, the aim of the present study is to
clarify the clinical relevance of ventricular tachyarrhythmias
identified by 24-h ambulatory (Holter) electrocardiogram
(ECG) in a large, unique, and prospectively evaluated
athletic population.
METHODS
Patient selection. The case records of the Institute of
Sports Science were reviewed from January 1984 to March
1999, and 355 athletes had been assessed with 24-h ambu-
latory (Holter) ECG (from a total population of 15,889
athletes), if they met the following criteria: 1) 3 PVDs on
resting 12-lead ECG (n  337); and/or 2) history of
palpitations (n  18).
Each of the 355 athletes underwent a cardiovascular
evaluation (in addition to 24-h Holter ECG monitoring),
including medical history and physical examination, 12-lead
ECG, two-dimensional echocardiography, symptom-
limited exercise ECG, and chest X-ray. Holter ECGs were
recorded during periods of active training and included an
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average of 1 h in a training session similar to that performed
by the athlete, with the remaining time occupied by usual
daily activities. Athletes with particularly frequent and
complex PVDs on ambulatory (Holter) ECG monitoring
were selected on a clinical basis to undergo additional
testing for the purpose of detecting or defining underlying
cardiovascular disease, including magnetic resonance imag-
ing (MRI) (n  42), nuclear scintigraphy (n  16),
endomyocardial biopsy (n  10), and electrophysiologic
(EP) study with programmed ventricular stimulation (n 
24). Of the 355 athletes included in the study population,
230 had been routinely examined at our institution as part of
the Italian national preparticipation screening program for
competitive athletes (10,11), and the other 125 athletes
were referred to us for cardiac evaluation because of a
suspicion of cardiovascular disease. Athletes were engaged
in 18 different sporting disciplines, most commonly soccer
(25%), basketball (14%), and volleyball (10%), and had
participated in vigorous training programs for one to 13
years (median four years); 110 (30%) had achieved interna-
tional recognition in World Championship and Olympic
Games; and 245 (70%) competed at the national level.
Mean age of the athletes at the time of Holter recording was
24.8  12.4 years (range 14 to 35 years). All 355 athletes
had periodic evaluations every 6 to 12 months over a
follow-up period of 2 to 15 years (mean 8.4  6.3 years).
The criteria used for the diagnosis of arrhythmogenic
right ventricular cardiomyopathy (ARVC) were those pre-
viously recommended (12). Diagnosis of myocarditis was
based on the histologic appearance of biopsy specimens in
accord with the Dallas criteria (13). Dilated cardiomyopathy
was diagnosed based on recognition of a dilated left ven-
tricular cavity (end-diastolic dimension60 mm) associated
with systolic left ventricular dysfunction (ejection fraction
45% and/or segmental wall motion abnormalities) (14). A
bicuspid aortic valve without hemodynamic evidence of
stenosis or significant valvular regurgitation was regarded
only as an echocardiographic finding rather than a true
abnormality. At the time of Holter monitoring, no athlete
was taking antiarrhythmic or other cardioactive medica-
tions.
EP studies. Twenty-four athletes with the most frequent
and complex arrhythmias on Holter ECG were selected on
clinical indications for EP study: 10 with 10,000
PVDs/24 h, nine with 10,000 PVDs and 1 nonsus-
tained ventricular tachycardia (NSVT), and five with
2,000 PVDs and 1 episode of NSVT. Eight of these 24
athletes also had palpitations. Ventricular stimulation was
performed using a programmable stimulator (Medtronic
5328, Minneapolis, Minnesota), delivering rectangular
pulses of 2 ms duration at twice the diastolic threshold. Up
to three extra stimuli were introduced after eight ventricular
paced beats at three drive cycle lengths (600, 500, and 400
ms) and in two right ventricular sites (apex and outflow
tract). In 18 athletes who were not inducible under basal
conditions, programmed stimulation was also carried out
with isoproterenol infusion.
Statistics. Age is expressed as the mean  SD (standard
deviation). For all other variables, frequency distributions
are reported. Differences between subgroups and multiple
tests analysis were assessed using Kruskal-Wallis analysis. A
two-tailed p value 0.05 was considered evidence of statis-
tical significance. Statistical analyses were performed using
BMPD Statistical Software (University of California, Los
Angeles, California) with 3S program (1995).
RESULTS
Frequency of PVDs. Based on the 24-h Holter ECG data,
the 355 athletes were segregated into three groups. Group A
was comprised of 71 athletes with both frequent and
complex PVDs (2,000 PVDs and 1 burst of NSVT/24
h). Group B consisted of 153 athletes with less frequent
arrhythmias (100 to 2,000 PVDs without NSVT/24 h).
Group C consisted of 131 athletes with 100 PVDs and
without NSVT/24 h (Table 1).
GROUP A. In the 71 Group A athletes, frequency of
PVDs/24 h ranged from 2,000 to 43,000 (mean 10,850 
7,500), including 24 (34%) who had 10,000 PVDs/24 h.
Each of the 71 athletes had 1 couplet (mean 70  22,
range 7 to 280). Thirty-eight of these 71 athletes (54%) also
had 1 to 179 bursts of NSVT (mean 4), consisting of 3 to 28
consecutive beats, at heart rates of 130 to 270 beats/min. In
addition, nine of 24 athletes with 10,000 PVDs had 1
run of NSVT (Fig. 1). Only 8 of the 71 Group A athletes
(11%) reported palpitations, and none had episodes of
impaired consciousness or other cardiac symptoms.
GROUP B. In the 153 athletes of Group B, PVDs ranged
from 100 to 1,890 (mean 1,211  850); eight athletes had
one couplet, but none had NSVT. Ten of the 153 Group B
athletes (6%) reported palpitations, and none had impaired
consciousness or other cardiac symptoms.
GROUP C. In the 131 athletes of Group C, PVDs ranged
from 3 to 98 (mean 55  22). No athlete in Group C had
couplets or NSVT or reported palpitations.
Cardiovascular abnormalities. OVERALL ATHLETE
GROUP. Of the 355 athletes, 329 (93%) showed no evidence
of relevant cardiovascular abnormalities based on clinical
Abbreviations and Acronyms
ARVC  arrhythmogenic right ventricular
cardiomyopathy
ECG  electrocardiogram
EP  electrophysiologic
LBBB  left bundle branch block
MRI  magnetic resonance imaging
NSVT  nonsustained ventricular tachycardia
PVD  premature ventricular depolarization
VA  ventricular arrhythmia
VT  ventricular tachycardia
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examination and noninvasive testing. The other 26 athletes
(7%) had cardiovascular abnormalities, all known to be
associated with VAs (15–17), including mitral valve pro-
lapse with mild-to-moderate regurgitation in 11, ARVC in
seven, myocarditis in four, and dilated cardiomyopathy in
four.
Table 1. Demographic and Clinical Data in 355 Competitive Athletes With Ventricular
Tachyarrhythmias
Group A
(>2,000 PVDs and
>1 NSVT)
Group B*
(>100 to
<2,000 PVDs)
Group C*
(<100 PVDs) p Value
No. athletes 71 153 131
Age 24  10 24  10 25  11 NS
Male:Female 51:20 120:33 102:29 NS
Palpitations† 8 (11%) 10 (6%) 0 0.0013
12-lead ECG abnormalities‡ 15 (21%) 5 (3%) 2 (1.5%)  0.001¶
Echo abnormalities§ 21 (30%) 8 (5%) 0  0.001¶
*NSVT was absent in these subgroups. †Defined as a frequent sensation of irregular heart beat (also during exercise),
unassociated with dizziness. ‡Increased R and/or S wave30 min, inverted T waves (2 leads), deep Q waves (2 mm), LBBB
or RBBB, left axis deviation. §Mitral valve leaflet redundancy and prolapse (n  11); dilated cardiomyopathy (end-diastolic
dimension 60 mm) associated with systolic left ventricular dysfunction (ejection fraction 45% and/or segmental wall motion
abnormalities) (n  4); segmental wall motion abnormalities consistent with either ARVC and myocarditis (n  11); and
bicuspid aortic valve without aortic regurgitation (n  3); Group A versus Group C and Group B versus Group C (p  0.05);
¶Group A versus Group B and Group A versus Group C (p  0.05).
ECG  electrocardiogram; Echo  two-dimensional echocardiography; NSVT  nonsustained ventricular tachycardia;
PVDs  premature ventricular depolarizations.
Figure 1. Segment of 24-h Holter electrocardiogram recording from a 24-year-old male basketball player with history of frequent palpitations. (Top)
Asymptomatic 10-beat burst of nonsustained ventricular tachycardia (shortest R-R interval, 300 ms). Intervals between the initial beat and subsequent
ectopic beats gradually shorten as the rate of discharge of the ectopic focus increases. The electrophysiologic study with programmed ventricular stimulation
was normal. (Bottom) Hourly profile of premature ventricular depolarizations (PVDs) over 24 h. There is a total of 12,186 PVDs during a 24 h period
largely without significant differences between the morning and evening. Only during a training session (at 3 PM) was there a distinctly reduced number
of PVDs (200/h).
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RELATIONSHIP OF CARDIOVASCULAR ABNORMALITIES TO
ARRHYTHMIA SUBGROUPS. Cardiovascular abnormalities
were significantly more common in Group A (21/71, 30%)
than in Group B (5/153, 3%) and Group C (0/131, 0%; p
0.001) (Table 2). Group A athletes with or without cardio-
vascular abnormalities did not differ with respect to PVDs,
couplets, and NSVT: those athletes with cardiovascular
abnormalities showed 8,411  11,000 PVDs, 60  108
couplets, and 6.2  6.1 NSVT bursts in 24 h of Holter
ECG recording; and those without abnormalities had
11,217  9,000 PVDs, 80  184 couplets, and 11  35
NSVT (p  0.05).
Morphology of PVDs and relationship to cardiovascular
abnormalities. Premature ventricular depolarizations with
left bundle branch block (LBBB) (frequently associated
with vertical axis) (Fig. 2) occurred with similar prevalence
in Groups A (46/71, 65%), B (120/153, 78%), and C
(88/131, 67%; NS). The occurrence of right bundle branch
block PVDs also did not differ significantly between Groups
A (19/71, 27%), B (36/153, 24%), and C (32/131; 24%;
Table 2. Prevalence of Structural Cardiovascular Abnormalities in 355 Competitive Athletes
With Ventricular Tachyarrhythmias
Group A
(>2,000 PVDs and
>1 NSVT)
Group B*
(>100 to <2,000 PVDs)
Group C*
(<100 PVDs) p Value
No. of athletes 71 153 131
ARVC 7 (10%) 0 0  0.001†
MVP 6 (9%) 5 (3%) 0 0.0042‡
Myocarditis 4 (5.5%) 0 0 0.0003†
DCM 4 (5.5%) 0 0 0.0003†
Totals 21 (30%) 5 (3%) 0  0.001†
*NSVT was absent in these subgroups; †Group A versus Group B and Group A versus Group C (p  0.05); and ‡Group A
versus Group C (p  0.05).
ARVC arrhythmogenic right ventricular cardiomyopathy; DCM dilated cardiomyopathy; MVPmitral valve prolapse;
Other abbreviations as in Table 1.
Figure 2. Resting 12-lead electrocardiogram (ECG) showing left bundle branch block premature ventricular depolarization pattern and inferiorly oriented
QRS axis from an asymptomatic 27-year-old soccer player. Otherwise, ECG pattern is normal. Noninvasive testing excluded underlying cardiovascular
abnormalities.
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NS). Of the 71 athletes in Group A, LBBB PVDs were
found more frequently in the absence (35/46; 76%) than in
the presence of structural cardiac disease (11/46; 24%; p 
0.001). No athletes in Groups B and C with LBBB PVDs
showed cardiovascular abnormalities.
Utility of invasive and noninvasive testing in the identi-
fication of cardiovascular abnormalities. The 12-lead
ECG failed to show evidence of Brugada and long QT
syndromes in any athlete, although T-wave inversion in
precordial leads V1–V3 raised a consideration for ARVC in
four athletes, ultimately diagnosed by MRI or myocardial
biopsy. Echocardiography identified mitral valve prolapse in
11 athletes and dilated cardiomyopathy in four. Of the 42
athletes who underwent MRI, cardiovascular abnormalities
were detected in 12, including six with ARVC. Ten athletes
had myocardial biopsy, and a diagnosis of cardiovascular
disease was made in 8 (myocarditis in 4 and ARVC in 4).
Most athletes showed no PVDs or NSVT during and
immediately after exercise testing, including 45 athletes in
Group A (65%), 110 in Group B (72%), and 122 in Group
C (93%). No athlete experienced cardiac symptoms (or
impaired consciousness) during exercise testing.
EP studies. In only one of the 24 athletes with EP studies
(a 32-year-old cyclist with ARVC and 12,000 PVDs and 5
NSVT bursts on Holter ECG) was sustained VT provoked
by programmed ventricular stimulation. In the other 23
athletes (13 without and 10 with cardiovascular abnormal-
ities), either no arrhythmia or only NSVT was induced. The
athlete who died with ARVC had refused to undergo EP
study.
Follow-up. Each of these 71 athletes with frequent and
complex VAs (Group A) was disqualified from competitive
sports for a minimum of three months, based on the Italian
guidelines for determining eligibility in competitive athletes
with cardiovascular abnormalities (18), which closely resem-
ble the recommendations of the 26th Bethesda Conference
(19).
Over the follow-up, one of these athletes, a 24-year-old
man with ARVC, died suddenly while participating in a
competitive field hockey game (against medical advice), six
months after official disqualification. This athlete had 2,100
PVDs and two bursts of NSVT (4 and 6 beats at 180/min)
on Holter recording and also had occasional palpitations.
The other 70 Group A athletes, as well as all Group B and
Group C athletes with less frequent arrhythmias, who were
allowed to resume competition and training, survived to the
end of the follow-up period without incurring cardiac
symptoms or events.
Pharmacologic treatment. Of the 71 athletes in Group A,
only eight (all with underlying cardiovascular diseases)
received drug treatment with beta-blockers (n  5),
propafenon (n  2), or enalapril (n  1). This treatment
was associated with reduction in the total number of PVDs
and/or of complex arrhythmias in five patients (mitral valve
prolapse in 2 and ARVC in 3). Specifically, three of these
athletes with 10,000 PVDs and NSVT showed the
disappearance of NSVT and reduction of PVDs to500/24
h with beta-blocker or propafenon treatment. The two
other athletes associated showed disappearance of NSVT
but persistence of PVDs (7,534  1,450 before vs. 6,880 
1,607 after drug treatment). In the remaining three patients,
drugs did not reduce ectopy (6,583  886 PVDs and 6  1
episodes of NSVT before vs. 6,286 PVDs and mean 5  1
episodes of NSVT after treatment). No athlete in Group B
or C received drugs.
DISCUSSION
Several ambulatory (Holter) ECG studies have shown VAs,
primarily PVDs, in a high proportion of apparently healthy
athletes and some normal untrained subjects (8,20–27). The
clinical assessment of these arrhythmias is of particular
significance because of the recognition that young, other-
wise healthy athletes can harbor unsuspected and potentially
lethal cardiovascular diseases, which can result in sudden
arrhythmic death (1–4). For these reasons, we thought it is
timely and important to analyze a large athletic population
with respect to ventricular tachyarrhythmias and the pres-
ence or absence of associated cardiovascular abnormalities.
Indeed, these observations potentially impact on clinical
decision making with respect to the eligibility (or disquali-
fication) of athletes with frequent and complex VAs partic-
ipating in intense sports training and competition (18,19).
To this purpose, we have examined the clinical signifi-
cance of ventricular tachyarrhythmias identified by ambula-
tory (Holter) ECG in a large population of 355 highly
trained athletes. Overall, only 7% of our athletes harbored
structural cardiovascular abnormalities that were the likely
cause of these arrhythmias, and prevalence of these struc-
tural abnormalities was 15 times higher in athletes with
frequent and complex ventricular tachyarrhythmias than in
those with less frequent arrhythmias. Nevertheless, over the
eight-year follow-up period, risk of sudden death proved to
be exceedingly low whether or not cardiovascular abnormal-
ities were present and despite the presence of complex VAs
that otherwise might reasonably imply a high risk of sudden
cardiac death. Indeed, just one athlete of the 355 died
suddenly during athletic competition (0.3%; annual mortal-
ity 0.17%), a 24-year-old field hockey player with ARVC,
which was associated with 2,100 PVDs and two brief runs
of NSVT, who continued competition against medical
advice.
Of note, the low-risk status of our athletes may be in part
attributable to the fact that we identified few examples of
those cardiac diseases known to be the most commonly
associated with sudden death in populations of trained
athletes, such as hypertrophic cardiomyopathy or the coro-
nary anomalies of wrong sinus origin (1–3). In the present
study, the most common anomaly associated with VAs was
mitral valve prolapse, and none of these athletes died
suddenly. Nevertheless, we wish to sound a note of caution
that certain cardiac diseases associated both with ventricular
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tachyarrhythmias and with sudden death in athletes (such as
myocarditis) (1,19) may be challenging to identify clinically
and require a high index of suspicion (28,29). Furthermore,
studies with MRI showed the presence of small areas of
fatty replacement in patients with apparently idiopathic
right outflow tract tachyarrhythmias (30,31), and we there-
fore we cannot exclude the possibility that some of our
athletes who did not undergo MRI and/or invasive testing
might have (mild) morphologic right ventricular abnormal-
ities responsible for VAs. However, considering the large
number of athletes with VAs reported in this study and their
favorable clinical outcome, we believe that it is exceedingly
unlikely such a rare disease could be responsible for the
arrhythmias identified in many of our athletes.
Furthermore, recent advances in laboratory DNA analysis
have demonstrated a genetic basis for some arrhythmogenic
syndromes unassociated with left ventricular hypertrophy
(long QT syndrome, Brugada syndrome, and polymorphic
VT) (32,33). Because molecular studies and mutational
analysis were not part of our study design, we cannot
definitively exclude the possibility that such uncommon
genetic disorders were present in a very small minority of
our athletes with VAs.
VAs in the absence of structural heart disease. Perhaps
the most difficult subgroup with regard to clinical practice
guidelines are those athletes with frequent and complex
VAs in the absence of structural heart disease. Such indi-
viduals present a clinical dilemma regarding their eligibility
for sports (18,19). Our longitudinal follow-up data are
persuasive in supporting the view that frequent and complex
ventricular tachyarrhythmias, very commonly detected with
ambulatory ECG (Holter) monitoring in trained athletes
without cardiovascular abnormalities, appear benign and
probably do not require alteration in athletic lifestyle (23–
27). In addition, our inability to induce sustained ventricular
tachyarrhythmias during EP study in the vast majority of
these athletes supports this recommendation. Furthermore,
we have assembled preliminary data showing that athletic
deconditioning has the effect of abolishing frequent and
complex VAs in most athletes (34). Consequently, it would
appear that such arrhythmias on Holter monitoring, even in
athletes subjected to the unique environmental conditions
and stress of intense sports training and competition (po-
tentially with alterations in blood volume and electrolytes),
do not convey an ominous prognosis in the absence of
underlying structural heart disease. On the other hand, it is
possible that disqualification from intensive training and
competition could have favorably influenced the outcome
and decreased the likelihood of sudden death in athletes
with particularly frequent and complex VAs in the absence
of cardiovascular abnormalities.
Utility of preparticipation cardiovascular evaluations.
Our findings also suggest that preparticipation cardiovascu-
lar evaluations are effective not only in identifying and
disqualifying athletes with VAs and ARVC but also in
possibly preventing sudden cardiac death (2). Supportive of
this view is our observation that the six athletes in this study
identified with ARVC and frequent and complex VAs, who
were disqualified from sports, have all survived to the
present (over an average five-year follow-up period). How-
ever, the other athlete with ARVC and frequent and
complex VAs died suddenly during competitive sports
activities; although this athlete showed frequent PVDs and
NSVT on Holter recording and was officially disqualified
from competition in accord with the Italian consensus panel
guidelines (18), he nevertheless continued to participate in
national level field hockey against medical advice. We can
only speculate that if this athlete had discontinued compet-
itive sports, his risk of having a sudden cardiac death would
have greatly diminished (1,19). Similar recommendations
for disqualification from intense competitive sports apply to
other heart diseases such as myocarditis, dilated cardiomy-
opathy, and mitral valve prolapse, particularly when they are
associated with frequent and complex VAs (19).
No sudden cardiac deaths occurred in athletes in whom
there were frequent and complex VAs without cardiovascu-
lar abnormalities, suggesting that these athletes do not
require restriction from competitive athletics.
Conclusions. In a highly trained athletic population pre-
senting with frequent and complex ventricular tachyarrhyth-
mias on ambulatory Holter ECG, only about one-third
harbored structural cardiovascular abnormalities likely to be
responsible for the irregularities (Group A). Therefore, such
arrhythmias were particularly common in the absence of
underlying disease and compatible with survival without
symptoms or cardiovascular events to the end of an eight-
year follow-up period. These findings underscore the view
that ventricular tachyarrhythmias in athletes subjected to
intense physical exertion during training and competition
do not usually develop unfavorable consequences and that,
in athletes without cardiovascular abnormalities, they would
appear to represent another previously unappreciated ex-
pression of the “athlete’s heart syndrome,” probably insuf-
ficient per se to definitively dictate withdrawal from com-
petitive sports.
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